unknown
Stage
About
Convergent Genomics develops a non-invasive genomic urine test called UroAmp to detect, monitor, and predict bladder cancer risks with high accuracy using next-generation sequencing of urine DNA.
Explore Convergent Genomics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.